Pirfenidone
Product Sizes
1 g
£ POA
HY-B0673-1G
200 mg
£ POA
HY-B0673-200MG
5 g
£ POA
HY-B0673-5G
100 mg
£ POA
HY-B0673-100MG
500 mg
£ POA
HY-B0673-500MG
10 g
£ POA
HY-B0673-10G
10mM/1mL
£ POA
HY-B0673-10MM
About this Product
- SKU:
- HY-B0673
- Additional Names:
- AMR69
- CAS Number:
- 53179-13-8
- Extra Details:
- Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].
- Molecular Weight:
- 185.23
- Purity:
- 99.99
- References:
- [1]Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):542-7.|[2]Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446(1-3):177-85.|[3]Yang Y, et al. Inhibition of Pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transitionof human lens epithelial cells line SRA01/04. PLoS One. 2013;8(2):e56837.|[4]Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16.|[5]Brooks D, et al. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018 May 4;9(34):23462-23481.
- Research Area:
- Inflammation/Immunology; Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- GPCR/G Protein;Immunology/Inflammation;Stem Cell/Wnt;TGF-beta/Smad
